Author

D. P. Elmer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 2

Frequent Co-Authors

F. Aberger· 3 shared C. G. Huber· 2 shared H.-H. Dang· 2 shared J. Horejs-Hoeck· 2 shared S. Grund-Groeschke· 2 shared S. Tesanovic· 2 shared A. Ramspacher· 1 shared A. Risch· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. Aberger

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemia

M. Luciano, C. Blöchl, J. Vetter, L. Urwanisch, T. Neuper, D. P. Elmer, R. Bauer, H.-H. Dang, H. Strandt, D. Neureiter, P. Krenn, S. Tesanovic, S. Rieser, O. Bergsleitner, L. Zell, , J. Horejs-Hoeck

This study shows that inhibiting the NLRP3 inflammasome reduces AML cell proliferation by promoting eIF2 phosphorylation and cell cycle arrest.

bioRxiv · Jun 25, 2021 · PreprintImmunology

Casein kinase 1D encodes a novel drug target in Hedgehog-GLI driven cancers and tumor-initiating cells resistant to SMO inhibition

E. Peer, S. K. Aichberger, F. Vilotic, G. Wolfgang, T. Parigger, S. Grund-Groeschke, D. P. Elmer, F. Rathje, A. Ramspacher, M. Zaja, S. Michel, S. Hamm, F. Aberger

This study identifies CSNK1D as a novel therapeutic target in Hedgehog-GLI driven cancers, showing its inhibition reduces tumor-initiating cell growth in both SMO-sensitive and -resistant settings.

bioRxiv · Jun 17, 2021Cancer Biology

Oncogenic GLI1 and STAT1/3 activation drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer cells

D. P. Elmer, V. Strobl, G. Stockmaier, H.-H. Dang, M. Wiederstein, D. Licha, A. Strobl, C. Sternberg, S. Tesanovic, S. Grund-Groeschke, W. Gruber, F. Wolff, R. Moriggl, A. Risch, R. Reischl, , F. Aberger

This study identifies IDO1-kynurenine pathway activation as a novel mechanism by which HH-IL6 and GLI-STAT signaling promote immunosuppression in skin cancer, suggesting combination therapy targeting these pathways.

bioRxiv · May 4, 2020 · PreprintCancer Biology